Physician profile
Todd Leslie
NPI 1831152156
$2,238.94
in general payments reported to CMS, 2019-2025
24 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.95 · 2020: $39.44 · 2021: $50.11 · 2022: $28.18 · 2023: $215 · 2024: $851 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $471.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $413.00 | 2022-2025 | |
| Lilly USA, LLC | $202.81 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $141.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $118.66 | 2023-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $115.99 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.28 | 2023-2025 | Xifaxan |
| Pfizer INC. | $96.48 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $95.15 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $65.43 | 2020-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.43 | 2024-2025 | Jardiance |
| Dexcom, INC. | $51.15 | 2023-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $43.20 | 2021-2024 | Freestyle Libre 3 |
| Baxter Healthcare | $35.78 | 2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $34.04 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $33.16 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $32.53 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $23.50 | 2025 | Spravato |
| Astellas Pharma US INC | $18.89 | 2025 | Veozah |
| Corcept Therapeutics | $17.19 | 2023 | Korlym |
| Biohaven Pharmaceuticals, INC. | $16.83 | 2021 | |
| Inspire Medical Systems, INC. | $16.50 | 2023 | Inspire |
| Allergan, INC. | $15.29 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Leslie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.